None listed
Conditions
Brief summary
Background: Perinatal depression (PND) affects up to 20% of mothers and can lead to pregnancy complications and impairments in child health, development, and mother-infant bonding. Blood-based biomarkers capable of predicting PND prior to symptom onset will enable timely and unbiased screening, early treatment, and improved outcomes. Aims: The current study will test the efficacy of blood-based biomarkers as a predictor for PND, and will evaluate the feasibility of using Dried Blood Spot (DBS) devices in clinical practice. user satisfaction of the DBS will also be assessed. Methods: Online surveys will collect information related to mothers' perinatal depression, distress, quality of life, and DBS satisfaction. Venous blood collection will be conducted at usual second trimester appointments. Finger prick blood samples using DBS devices will be collected at 24 weeks gestation, 6 weeks postpartum, and 6 months postpartum. Outcomes: We expect that blood-based biomarkers will predict PND, and that the DBS device will be feasible and acceptable to participants.
Interventions
The Capitainer B Dried Blood Spot (DBS) test involves the removal of blood from a participant using a finger prick blood sampling device. The blood is then immediately applied to a pre-prepared DBS filter paper for drying. This paper card is then collected for analysis. This process takes less than 10 seconds to complete.
The DBS test will be evaluated for its ability to predict perinatal depression in a hospital setting. Women will be shown how to use the finger prick blood sampling device at
The Capitainer B Dried Blood Spot (DBS) test involves the removal of blood from a participant using a finger prick blood sampling device. The blood is then immediately applied to a pre-prepared DBS filter paper for drying. This paper card is then collected for analysis. This process takes less than 10 seconds to complete. The DBS test will be evaluated for its ability to predict perinatal depression in a hospital setting. Women will be shown how to use the finger prick blood sampling device at their routine second trimester appointment by a member of the research team. The first sample will be conducted with a member of the research team to ensure participants' understand how to use the device. They will be asked to conduct blood sampling using the device in their home at 6 weeks postpartum and 6 months postpartum. These samples will be posted to the research team for analysis.
Sponsors
Mater Misericordiae
Study design
Allocation
Non-randomised trial
Intervention model
Single group
Primary purpose
Diagnosis
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Women attending the public or private maternity clinics at Mater Mothers’ Hospital in South Brisbane or Catherine’s House for Mothers, Babies and Families; pregnant prior to 24 weeks gestation; aged 18 years or above; have English proficiency.
Exclusion criteria
Women who have inability to access a device to receive email or text messages and to complete online surveys; Unable to provide informed consent
Outcome results
None listed